Inhibikase Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Wilmington, DE
IKT chart
What traders are saying about $IKT
Latest postsInhibikase Therapeutics, Inc. news
- Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026
Yahoo Finance ·
- Inhibikase Therapeutics, Inc. Stock Price Prediction: Today, Tomorrow, Next Week (IKT)
Traders Union ·
- Inhibikase Therapeutics, Inc. Stock Price Today | IKT Live Chart & News
Traders Union ·
- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Stock Has Consensus Target Price of $4.75
MarketBeat ·
- Inhibikase Appoints Scott Wasserman to Board of Directors
The Globe and Mail ·
- Form 4 Inhibikase Therapeutics Inc: Scott M. Wasserman (Director) For: 19 October
Investing.com Canada ·
- A director receives 310,000 options at Inhibikase Therapeutics (IKT), with service-based vesting.
Stock Titan ·
- Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
Yahoo Finance ·
- Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
Yahoo Finance ·
- Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
Yahoo Finance ·
- Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
Yahoo Finance ·
Inhibikase Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | $0 | $260,501 | $123,440 |
| Net income | -$48.3M | -$27.5M | -$19.0M | -$18.1M |
| Diluted EPS | $-0.49 | $-1.16 | $-3.16 | $-4.28 |
| Total assets (year end) | $181.2M | $98.6M | $14.5M | $24.9M |
| Cash and equivalents (year end) | $178.8M | $97.5M | $9.2M | $7.2M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Inhibikase Therapeutics, Inc.
- Ticker
- IKT (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Wilmington, DE
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1750149
Frequently asked questions
What exchange is Inhibikase Therapeutics, Inc. listed on?
Inhibikase Therapeutics, Inc. trades on the Nasdaq under the ticker symbol IKT.
What industry is Inhibikase Therapeutics, Inc. in?
Inhibikase Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Inhibikase Therapeutics, Inc. headquartered?
Inhibikase Therapeutics, Inc.'s business address on file with the SEC is in Wilmington, DE.
When does Inhibikase Therapeutics, Inc.'s fiscal year end?
Inhibikase Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Inhibikase Therapeutics, Inc. report?
Inhibikase Therapeutics, Inc. reported $0 in revenue for calendar year 2024, according to its SEC filings.